Journey Medical Corp

Overview

Compare with Tango Therapeutics (United States), Nuvation Bio Inc. or Fortress Biotech, or pick any stock.

• TickerDERM on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersScottsdale, Arizona¹
• Incorporated inDE³
• Business address9237 E Via De Ventura Blvd., Suite 105, Scottsdale, Az 85258³
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”).⁵ From its latest annual report

Corporate structure

Journey Medical Corp is part of a group headed by Fortress Biotech. 11 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Journey Medical Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our executive offices are located at 9237 E Via de Ventura Blvd. Suite 105, Scottsdale, AZ 85258. The term of the lease for this space commenced on February 2025 and will expire on February 28, 2027, and we pay an average annual rent of $0.1 million. We believe that our existing facilities are adequate to meet our current requirements. We do not own any real property.

Item 2 of the 10-K filed Mar 26, 2026.⁵

Leadership

Who has led Journey Medical Corp, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerClaude Maraoui Nov 26, 2021 to now¹⁴
• PresidentClaude Maraoui Nov 26, 2021 to now¹⁴
• Chief financial officerJoseph Benesch Jan 31, 2023 to now¹⁵
• Chief financial officerPaolantonio Ernest Robert De Nov 26, 2021 to Oct 6, 2022¹⁶
• Chief operating officerRamsey Alloush Apr 4, 2025 to now¹⁷

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Serves as Interim Chief Financial OfficerRobyn Hunter named Oct 5, 2021²⁵
• DirectorJustin Smith named Oct 5, 2021²⁵

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• JG Pharma Inc. Delaware⁴

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

1. Aug 12, 20268-K Results of operations²⁶
2. Jun 26, 20268-K Shareholder vote²⁷
3. May 13, 20268-K Results of operations²⁸
4. Apr 21, 20268-K Other events²⁹
5. Mar 25, 20268-K Results of operations³⁰
6. Nov 12, 20258-K Results of operations³¹
7. Sep 26, 20258-K Entered a material agreement; New debt or obligation³²
8. Aug 28, 20258-K Entered a material agreement; Ended a material agreement³³
9. Aug 12, 20258-K Results of operations³⁴
10. Jul 14, 20258-K Other events³⁵
11. Jun 26, 20258-K Bylaws or fiscal year changed; Shareholder vote³⁶
12. Jun 24, 20258-K Other events³⁷
13. Nov 26, 2021New chief executive Claude Maraoui becomes CEO¹⁴

Calendar

Coming up

1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.09) a share, on Nov 12, 2025.³⁸

When it reported results

1. Aug 12, 2026Reported quarterly or annual results²⁶
2. May 13, 2026Reported quarterly or annual results²⁸
3. Mar 25, 2026Reported quarterly or annual results³⁰
4. Nov 12, 2025Reported quarterly or annual results³¹
5. Aug 12, 2025Reported quarterly or annual results³⁴
6. May 14, 2025Reported quarterly or annual results³⁹
7. Mar 26, 2025Reported quarterly or annual results⁴⁰
8. Feb 5, 2025Reported quarterly or annual results⁴¹

Drug trials and FDA: recently

1. Nov 1, 2024FDA approval FDA approved Emrosi (minocycline hydrochloride) (NDA 219015).⁴²

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

222 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 88 insider forms, 12 large holders, 1 private raises, 53 other. The latest 20:

1. Oct 9, 2026SCHEDULE 13G/A EDGAR
2. Aug 12, 202610-Q EDGAR
3. Aug 12, 20268-K EDGAR
4. Jul 31, 2026SCHEDULE 13G/A EDGAR
5. Jul 15, 2026SCHEDULE 13G/A EDGAR
6. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
7. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
8. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
9. Jun 29, 20264 OWNERSHIP DOCUMENT EDGAR
10. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
11. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
12. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
13. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
14. Jun 26, 20268-K EDGAR
15. May 13, 202610-Q EDGAR
16. May 13, 20268-K EDGAR
17. Apr 30, 2026SCHEDULE 13G EDGAR
18. Apr 30, 2026DEFA14A EDGAR
19. Apr 30, 2026DEF 14A EDGAR
20. Apr 24, 20264 OWNERSHIP DOCUMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 9 buys and 23 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• WASATCH ADVISORS LPSCHEDULE 13G/A, 5 filings May 13, 2025 to Oct 9, 2026⁴³
• VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Apr 30, 2026 to Jul 31, 2026⁴⁴
• TANG CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Nov 29, 2024 to May 15, 2025⁴⁵
• BRC Group Holdings, IncSC 13G/A, 2 filings Feb 11, 2022 to Dec 29, 2022⁴⁶
• Fortress BiotechSC 13G, 1 filing Aug 17, 2022⁴⁷

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Mar 31, 2021Raised $19 million in a private offering of equity²⁵ Form D: $30 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 71. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Journey Medical Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARJourney Medical Corp¹
• CIK0001867066
• Employer ID (EIN)47-1879539⁵
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address9237 E Via De Ventura Blvd., Suite 105, Scottsdale, AZ 85258¹
• Phone480-434-6670¹
• Shares outstanding6,000,000 Common Class A shares; 21,330,696 Common Excluding Class shares as of Mar 25, 2026⁵
• Public float$84.7M as of Jun 30, 2025⁵
• AuditorKPMG LLP, Short Hills, New Jersey PCAOB ID 185; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceJul 22, 2021¹
• Filings229 in all: 4 (75), 8-K (48), 10-Q (15), 3 (11), UPLOAD (9), CORRESP (8), SCHEDULE 13G/A (6), 10-K (5)¹
  All 32 form types

  424B3 (5), DEF 14A (5), DEFA14A (5), S-1/A (4), S-8 (4), EFFECT (3), SC 13G (3), DRS (2), DRS/A (2), DRSLTR (2), S-3 (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 3/A (1), 4/A (1), 424B5 (1), 8-A12B (1), CERT (1), D (1), D/A (1), NT 10-Q (1), PRE 14A (1), S-1 (1), SC 13G/A (1)

• Latest filingsAnnual report (10-K) Mar 26, 2026
  Quarterly report (10-Q) Aug 12, 2026
  Proxy statement (DEF 14A) Apr 30, 2026
  Latest 8-K (8-K) Aug 12, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks Journey Medical Corp names in Item 1A of its 10-K filed Mar 26, 2026: 68 risks under these headings, as written.⁵

• Risks Related to Our Business, Industry and Existing Operating Revenue Stream
• Future revenue from sales of our dermatology products may be lower than expected or lower than in previous periods.
• We face challenges as our products face generic competition and/or losses of exclusivity.
• Any disruptions to the capabilities, composition, size or existence of our field sales force may have a significant adverse impact on our existing revenue stream. Further, our ability to effectively market and sell any future products that we may develop will depend on our ability to establish and maintain sales and marketing capabilities or to enter into agreements with third parties to market, distribute and sell any such products.
• Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.
• If the FDA does not conclude that a product candidate satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidate under Section 505(b)(2) are not as we expect, the approval pathway for the product candidate will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.
• If any of our contract manufacturers fails to produce our products in the volumes that we require on a timely basis, or to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the commercialization of our products or development and commercialization of any future product candidate, if approved, or be unable to meet market demand, and may lose potential revenues.
• If serious adverse events are identified during the development of any future product candidates, we may need to abandon or limit our development of these product candidates.
• All of our current and future products will remain subject to substantial regulatory scrutiny even after receiving regulatory approval.
• Our current and future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.
• Our products and future product candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, which could harm our business.
• Public concern regarding the safety of any of our products and any future product candidates could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to incur additional costs.

Legal proceedings

To our knowledge, there are no legal proceedings pending against us, other than routine actions, administrative proceedings, and other actions not deemed material, that are expected to have a material adverse effect on our financial condition, results of operations, or cash flows. In the ordinary course of business, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages.

On February 25, 2026, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware (‘the Court”) against Lupin Limited, Lupin Inc., and Lupin Pharmaceuticals, Inc. (“Lupin”). This lawsuit was filed following receipt of a “paragraph IV certification” notice from Lupin regarding its respective filing of an ANDA with the FDA seeking approval to engage in the commercial manufacture, use or sale of a generic version of Emrosi in the U.S. prior to the expiration of certain of the Company’s U.S. patents. The notice alleged that certain of the Company’s patents related to Emrosi, with expiration dates through 2039 are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the proposed generic products. The Company intends to vigorously defend its intellectual property. The filing of each lawsuit within 45 days of receipt of each of the respective notices triggered stays of FDA approval of each of the respective ANDAs for up to 30 months in accordance with the Hatch-Waxman Act.

The opening of Item 3, Legal Proceedings.⁵